TY - JOUR
T1 - Recent Advances in Treatment of Systemic Sclerosis and Morphea
AU - Teske, Noelle
AU - Fett, Nicole
N1 - Publisher Copyright:
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023.
PY - 2024/3
Y1 - 2024/3
N2 - Systemic sclerosis (SSc) and morphea are autoimmune sclerosing diseases that cause significant morbidity, and in the case of SSc, mortality. The pathogenesis of both SSc and morphea share vascular dysfunction, auto-reactive T cells and Th2-associated cytokines, such as interleukin 4, and overproduction of transforming growth factor beta (TGFβ). TGFβ stimulates fibroblast collagen and extra-cellular matrix production. Although morphea and SSc have similar pathogenic pathways and histological findings, they are distinct diseases. Recent advances in treatment of morphea, skin sclerosis in SSc, and interstitial lung disease in SSc are focused on targeting known pathogenic pathways.
AB - Systemic sclerosis (SSc) and morphea are autoimmune sclerosing diseases that cause significant morbidity, and in the case of SSc, mortality. The pathogenesis of both SSc and morphea share vascular dysfunction, auto-reactive T cells and Th2-associated cytokines, such as interleukin 4, and overproduction of transforming growth factor beta (TGFβ). TGFβ stimulates fibroblast collagen and extra-cellular matrix production. Although morphea and SSc have similar pathogenic pathways and histological findings, they are distinct diseases. Recent advances in treatment of morphea, skin sclerosis in SSc, and interstitial lung disease in SSc are focused on targeting known pathogenic pathways.
UR - http://www.scopus.com/inward/record.url?scp=85179350181&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85179350181&partnerID=8YFLogxK
U2 - 10.1007/s40257-023-00831-2
DO - 10.1007/s40257-023-00831-2
M3 - Review article
C2 - 38087156
AN - SCOPUS:85179350181
SN - 1175-0561
VL - 25
SP - 213
EP - 226
JO - American Journal of Clinical Dermatology
JF - American Journal of Clinical Dermatology
IS - 2
ER -